Clinical implications of germline mutations in breast cancer genes: RECQL A. Ramsay BowdenMarc Tischkowitz Review Open access 04 January 2019 Pages: 553 - 560
National consensus recommendations on patient-centered care for ductal carcinoma in situ Anna R. GagliardiFrances C. WrightRebecca Warburton Review Open access 09 January 2019 Pages: 561 - 570
PD-L1 expression in breast cancer: expression in subtypes and prognostic significance: a systematic review Elisabeth Specht StovgaardAnne Dyhl-PolkDorte Nielsen Review 10 January 2019 Pages: 571 - 584
Health-related quality of life of breast cancer patients in the Eastern Mediterranean region: a systematic review and meta-analysis Seyed-Mehdi HashemiAbbas BalouchiMansoureh Ashghali Farahani Review 10 January 2019 Pages: 585 - 596
Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials Fausto PetrelliAntonio GhidiniSandro Barni Review 18 January 2019 Pages: 597 - 604
A common Chk1-dependent phenotype of DNA double-strand break suppression in two distinct radioresistant cancer types Patrick H. DinkelborgMeng WangHenning Willers Preclinical study 03 January 2019 Pages: 605 - 613
Synergistic anti-cancer activity of CDK4/6 inhibitor palbociclib and dual mTOR kinase inhibitor MLN0128 in pRb-expressing ER-negative breast cancer Takuro YamamotoNoriko KanayaShiuan Chen Preclinical study 03 January 2019 Pages: 615 - 625
Clinicopathological analysis of homologous recombination-deficient breast cancers with special reference to response to neoadjuvant paclitaxel followed by FEC Seiichi ImanishiYasuto NaoiShinzaburo Noguchi Preclinical study 03 January 2019 Pages: 627 - 637
Prevalence and characterization of ATM germline mutations in Chinese BRCA1/2-negative breast cancer patients Ziguo YangTao OuyangYuntao Xie Preclinical study 03 January 2019 Pages: 639 - 647
Epithelial-to-mesenchymal transition status of primary breast carcinomas and its correlation with metastatic behavior C. D. Savci-HeijinkH. HalfwerkM. J. van de Vijver Preclinical study Open access 04 January 2019 Pages: 649 - 659
Expression of Lamin A/C in early-stage breast cancer and its prognostic value I. M. AlhudiriC. C. NolanC. J. Chapman Preclinical Study 04 January 2019 Pages: 661 - 668
Three-dimensional tumor visualization of invasive breast carcinomas using whole-mount serial section histopathology: implications for tumor size assessment G. M. ClarkeC. M. B. HollowayM. J. Yaffe Preclinical study 05 January 2019 Pages: 669 - 677
Tumor microenvironmental plasmacytoid dendritic cells contribute to breast cancer lymph node metastasis via CXCR4/SDF-1 axis Ramy GadallaHebatallah HassanMona Mostafa Mohamed Preclinical study 10 January 2019 Pages: 679 - 691
Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study Alberto OcanaMarta Gil-MartinManuel Ruiz-Borrego Clinical trial 03 January 2019 Pages: 693 - 701
Is microductectomy still necessary to diagnose breast cancer: a 10-year study on the effectiveness of duct excision and galactography Daniel Ben LustigRebecca WarburtonElaine C. McKevitt Clinical trial 03 January 2019 Pages: 703 - 709
Extracapsular extension in the positive sentinel lymph node: a marker of poor prognosis in cT1-2N0 breast cancer patients? Marissa L. G. VaneMaria A. WillemsenMarjolein L. Smidt Clinical trial 04 January 2019 Pages: 711 - 718
Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up H. S. RugoR. S. FinnD. J. Slamon Clinical trial Open access 10 January 2019 Pages: 719 - 729
Palbociclib and endocrine therapy in heavily pretreated hormone receptor-positive HER2-negative advanced breast cancer: the UK Compassionate Access Programme experience Nicolò Matteo Luca BattistiBelinda KingstonStephen Johnston Clinical trial 17 January 2019 Pages: 731 - 740
Folic acid supplement use and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a case–control study Shana J. KimCindy X. W. ZhangJoanne Kotsopoulos Epidemiology 02 January 2019 Pages: 741 - 748
Pre-diagnostic sex hormone levels and survival among breast cancer patients Kevin H. KenslerA. Heather EliassenRulla M. Tamimi Epidemiology 02 January 2019 Pages: 749 - 758
Comparison of treatment of early-stage breast cancer among Nurses’ Health Study participants and other Medicare beneficiaries Andrea M. AustinNirav S. KapadiaAnna N. A. Tosteson Epidemiology 03 January 2019 Pages: 759 - 767
Age-specific risks of incident, contralateral and ipsilateral breast cancer among 1776 Polish BRCA1 mutation carriers Jan LubinskiTomasz HuzarskiSteven A. Narod Epidemiology 05 January 2019 Pages: 769 - 774
BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients Alex FriedlaenderAurélie VuilleumierS. Intidhar Labidi-Galy Epidemiology 11 January 2019 Pages: 775 - 783
Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors Xiaoqing XuRowan T. ChlebowskiReina Haque Epidemiology 18 January 2019 Pages: 785 - 794
Re-testing of predictive biomarkers on surgical breast cancer specimens is clinically relevant Stephanie RobertsonCaroline RönnlundJohan Hartman Epidemiology Open access 18 January 2019 Pages: 795 - 805
Re: The relationship between patient and tumor characteristics, patterns of breast cancer care, and 5-year survival among elderly women with incident breast cancer. Breast Cancer Res Treat. Sep 2018;171(2):477-488 Elvin S. ChengXue Qin Yu Letter to the Editor 04 January 2019 Pages: 807 - 807
